Immunology and Microbiology
Adjuvant
18%
Adoptive Immunity
20%
Allogeneic Stem Cell Transplantation
15%
Allotransplantation
17%
Allotransplantation
9%
Alphavirus
20%
Antibody Response
13%
Antigen
43%
Antigen-Presenting Cell
16%
Autoantibodies
19%
Conditioning
10%
Cyclophosphamide
9%
Cytosol
14%
Cytotoxic T Cell
64%
Epitope
33%
HLA Antibody
76%
HLA Antigen
9%
Human Leukocyte Antigen
46%
Human Papillomavirus Type 16
29%
Humoral Immunity
11%
Immune Complex
28%
Immune Response
20%
Immune System
11%
Immunoassay
10%
Immunogenicity
12%
Immunotherapy
10%
Influenza
55%
Influenza Vaccine
27%
Influenza Virus
16%
ISCOM
9%
Kidney Transplantation
50%
MHC Class I
17%
Monospecific Antibody
67%
Mouse
31%
Myeloid
12%
Prednisolone
9%
Prevalence
9%
Semliki Forest Virus
28%
Solid
9%
Stem Cell
9%
Subunit Vaccine
19%
Systemic Lupus Erythematosus
9%
T Cell
28%
T Helper Cell
10%
Transplant Procedure
66%
Vaccination Policy
18%
Vaccine Efficacy
66%
Vaccine Immunogenicity
9%
Virosome
100%
Virus Inactivation
18%
Medicine and Dentistry
Acute Myeloid Leukemia
10%
Adeno-Associated Virus
9%
Allotransplantation
18%
Alphavirus
9%
Antibodies
9%
Antigen
34%
Antigen Presenting Cell
9%
Antiinfective Agent
9%
Autoantibodies
12%
Biological Marker
9%
Carcinogenesis
9%
Cellular Immunity
21%
Cervical Cancer
15%
Complement Component C3d
9%
Cyclophosphamide
9%
Cytotoxic T-Cell
27%
Dendritic Cell
10%
Disease
16%
Double Stranded DNA
9%
Fusion Protein
9%
Gene Targeting
9%
Glomerulus Basement Membrane
9%
Graft Failure
21%
Graft Survival
15%
Heterodimer
9%
HLA Antibody
27%
Human Leukocyte Antigen
9%
Human Papillomavirus Type 16
18%
Immune System
10%
Immunosuppressive Treatment
9%
Immunotherapy
10%
Intestine Transplantation
9%
Invasive Procedure
9%
ISCOM
9%
Kidney Allograft
9%
Kidney Graft
21%
Kidney Transplantation
19%
Liposome
11%
Major Histocompatibility Complex
9%
Memory B Cell
9%
Myeloid Malignancy
9%
Neoplasm
27%
Neutrophil Cytoplasmic Antibody
9%
Paraneoplastic Pemphigus
9%
Posttransplant Lymphoproliferative Disease
9%
Semliki Forest Virus
11%
Systemic Lupus Erythematosus
9%
T-Cell Response
9%
Vasculitis
9%
Virosome
46%
Keyphrases
Acceptable Mismatch
9%
Ankylosing Spondylitis
9%
Antibody Assay
9%
Antigen Delivery System
9%
Antigen-specific T Cell Response
9%
Cancer Induction
9%
Cross-priming
9%
Cytotoxic T Lymphocytes
9%
DDX41
9%
Deceased Donor Transplant
10%
Dendritic Cells
9%
DRB3
9%
Encapsulated Proteins
10%
Full-length Sequence
9%
Genetic Immunization
9%
Graft Failure
9%
Highly Sensitized Patients
9%
HLA Antibodies
9%
HLA Class I Molecules
9%
HLA Class II Alleles
9%
Human Leukocyte Antigen
9%
Human Leukocyte Antigen Antibodies
18%
Immunostimulating
9%
Influenza H5N1
9%
Interlocus Recombination
9%
Intranasal Vaccination
9%
Kidney Graft Survival
9%
Kidney Transplant Recipients
9%
Kidney Transplantation
11%
LpxL1
9%
Lymphocyte Activity
9%
Membrane Analysis
9%
Microneedle Array
9%
Mobilization Failure
9%
Multiplex
9%
Multiplex Bead Assay
9%
Paired Kidney Analysis
9%
PIRCHE
13%
Protein Antigen
21%
Questionable Expression
9%
Rho GDP Dissociation Inhibitor 2
9%
Single Antigen Bead
10%
T Cell Epitope
9%
TNF-α Blocking Agents
9%
Transcutaneous Immunization
9%
Trimethyl chitosan Nanoparticles
9%
Vaccine Delivery System
9%
Vaccine Development
9%
Virosomes
18%
Whole Inactivated Virus
9%
